Abstract
In this data paper we present a study of RNA expression in association with the disease course of acute myeloid leukemia (AML). We have previously identified aldehyde dehydrogenase genes ALDH1A1 and ALDH2 as prospective actionable targets in AML. ALDH1A1 is expected to have key functions in leukemia stem-like cells that are prone to a dormant state in terms of metabolic activity and proliferation. Cells with a higher activity of metabolism as a whole and in mitochondria in particular, are likely to generate a higher abundance of formaldehyde and acetaldehyde. Cell survival necessitates removal of formaldehyde and acetaldehyde, which is to a substantial degree the function of ALDH2. AML cells with a mutant NPM1 gene permit higher MYC activity which would lead to increased metabolic activity. Extended MYC activity is allowed by the mutant NPM1 protein, compared to NPM1 wild-type. Here, we show that survival analysis in patients with NPM1 mutant AML yields a higher hazard ratio for ALDH2 RNA than for ALDH1A1, which is not the case for patients with wild-type NPM1. This result is consistent with the difference in enzymatic function between ALDH2 and ALDH1A1, the latter of which is not suited for small aldehydes, especially formaldehyde. This should open the door to the examination of ALDH2 inhibitors such as the clinically approved disulfiram, for the treatment of NPM1 mutant AML that proves refractory to ALDH1A1 inhibition.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://kmplot.com/analysis/index.php?p=service&cancer=aml
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online from https://kmplot.com/analysis/index.php?p=service&cancer=aml.